A mathematical approach for the simultaneous in vitro spectrophotometric analysis of rifampicin and isoniazid from modified-release anti-TB drug delivery systems.
Dissolution testing with subsequent analysis is considered as an imperative tool for quality evaluation of the combination rifampicin-isoniazid (RIF-INH) combination. Partial least squares (PLS) regression has been successfully undertaken to select suitable predictor variables and to identify outliers for the generation of equations for RIF and INH determination in fixed-dose combinations (FDCs). The aim of this investigation was to ascertain the applicability of the described technique in testing a novel oral FDC anti-TB drug delivery system and currently available two-drug FDCs, in comparison to the United States Pharmacopeial method for analysis of RIF and INH Capsules with chromatographic determination of INH and colorimetric RIF determination. Regression equations generated employing the statistical coefficients satisfactorily predicted RIF release at each sampling point (R(2)>or=0.9350). There was an acceptable degree of correlation between the drug release data, as predicted by regressional analysis of UV spectrophotometric data, and chromatographic and colorimetric determination of INH (R(2)=0.9793 and R(2)=0.9739) and RIF (R(2)= 0.9976 and R(2)=0.9996) for the two-drug FDC and the novel oral anti-TB drug delivery system, respectively. Regressional analysis of UV spectrophotometric data for simultaneous RIF and INH prediction thus provides a simplified methodology for use in diverse research settings for the assurance of RIF bioavailability from FDC formulations, specifically modified-release forms.
University of the Witwatersrand, Department of Pharmacy and Pharmacology, Division of Pharmaceutics, Johannesburg, South Africa.
Lisa
L
du Toit
Viness
V
Pillay
Yahya
Y
Choonara
D000995:Antitubercular Agents / Q000032:analysis*; D002851:Chromatography, High Pressure Liquid; D003124:Colorimetry; D016503:Drug Delivery Systems; D019075:Electrophoresis, Capillary; D066298:In Vitro Techniques; D007538:Isoniazid / Q000032:analysis*; D012293:Rifampin / Q000032:analysis*; D013056:Spectrophotometry, Ultraviolet
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin